At the defined thresholds, the OST is as good as FRAX without BMD in identifying a low-risk population subgroup for whom screening BMD can reasonably be omitted. This could reduce costs and improve access to treatment.
No takes yet. Share an insight, caveat, or question.
Klinger et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: